Bristol Myers' cancer drug Augtyro wins new accelerated approval in solid tumors
Bristol Myers Squibb’s 2022 buyout of Turning Point Therapeutics for $4.1 billion continues to score wins at the FDA. On Thursday, the agency announced that a drug acquired as part of the deal,...
View ArticleTelix Pharmaceuticals pulls Nasdaq listing plans just before trading was to...
Telix Pharmaceuticals is no longer going to list on the Nasdaq, the company announced Thursday evening, pulling its US IPO shortly before it was to start trading. Telix was planning for a roughly $200...
View ArticleXtalPi raises $115M from Hong Kong IPO to expand AI drug R&D services
Chinese AI drug discovery company XtalPi has landed on the Hong Kong stock exchange after nearly $115 million ($896.13 million HKD) from an IPO. XtalPi, which is listing under the name QuantumPharm,...
View ArticleClik here to view.
Bill Haney gives up CEO post at Skyhawk, becomes chairman; Bayer parts ways...
Bill Haney → Bill Haney has helped Skyhawk Therapeutics stand out in the wave of biotechs looking to drug RNA, taking over from fellow co-founder Kathleen McCarthy early in its history and engineering...
View Article#ADA24: Innovent details Phase 3 weight loss data from Lilly-partnered GLP-1...
Innovent Biologics has lifted the curtain on late-stage data from its next-generation “double-G” drug in overweight or obese Chinese patients after the company teased in January that the trial...
View Article#EHA24: Roche details overall survival data on bispecific antibody Columvi
Roche released detailed data at the European Hematology Association congress for its CD20xCD3 bispecific antibody Columvi in earlier lines of large B cell lymphoma, showing just how much the drug...
View ArticleStephen Squinto talks writing checks and next-gen obesity drugs as JP Morgan...
Over a year and a half since its inception, JP Morgan’s life sciences investment arm has closed its first biotech venture capital fund with over $500 million. JP Morgan Life Sciences Private Capital...
View ArticleTakeda signs option deal for TKI inhibitor; Enveda's $55M raise
Plus, news about IN8bio, Rezolute, BeiGene and NewBridge: Takeda, Ascentage ink option deal: The deal involves a compound called olverembatinib, which Takeda described as an oral BCR-ABL TKI inhibitor...
View ArticleAutoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling...
In 30 patients with a number of autoimmune conditions who received Kyverna Therapeutics’ CAR-T cell therapy, 21 were able to stop taking their immune disease medications. The results mark one of the...
View ArticleClik here to view.
Vaxart wins $453M in BARDA funding for oral Covid-19 vaccine
The Biomedical Advanced Research and Development Authority (BARDA) has granted up to $453 million to Vaxart to revive its work on an oral Covid-19 vaccine, backing a technology that had seemingly...
View ArticleRare pediatric disease vouchers face uncertain future after September
Congress has until the end of September to reauthorize a voucher program that’s meant to incentivize new drug development for rare pediatric diseases. But the program faces a tough congressional...
View ArticleEnding 'product hopping' and other patent changes could save US $3B over a...
The Congressional Budget Office predicted that a patent reform bill introduced last year could result in federal savings of more than $3 billion over the next 10 years. The Affordable Prescriptions for...
View ArticleClik here to view.
FDA asks Covid-19 vaccine makers to instead target KP.2 strain for fall season
The FDA is directing Covid-19 vaccine manufacturers to update their formulations to target the KP.2 strain of the virus, citing higher circulation levels of that strain in recent weeks. Last week, the...
View ArticleBIO CEO’s patriotic pivot; Step forward for Lilly’s Alzheimer’s drug;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleGilead cancer drug magrolimab showed worrying trends around death
A Gilead cancer drug whose developments have essentially been halted not only failed to improve survival odds for blood cancer patients but also came with worrying safety risks — including a higher...
View ArticleWith new data, AstraZeneca makes the case for its BTK inhibitor in a...
Combined with chemotherapy and immunotherapy, AstraZeneca’s Calquence reduced the risk of disease progression or death by 27% compared to placebo and chemoimmunotherapy in first-line mantle cell...
View ArticleNurix’s protein degrader overcomes resistance to BTK mutations in small...
Preliminary results from a small study of heavily treated patients with blood cancer suggest that an experimental protein degrader, which removes problematic proteins instead of just inhibiting them,...
View ArticleGSK readies Blenrep's commercial re-launch in the US, and a push in second line
GSK is gearing up for the revival of multiple myeloma drug Blenrep, having hung onto the salesforce that was assembled when the drug first nabbed accelerated approval in 2020, only to be pulled after a...
View ArticleMerck's 21-valent pneumococcal vaccine for adults wins FDA approval
Merck’s 21-valent pneumococcal vaccine was approved by the FDA on Monday, bringing a new competitor to market for Pfizer’s 20-valent product. Merck’s vaccine, called Capvaxive, was specifically...
View ArticleClik here to view.
Philips works on tech to connect disparate healthcare and bio-tracking devices
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) As more medical devices that measure biodata show up in the market, healthcare electronics giant Philips...
View Article